Coverage policy updates

Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.

Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.

Recorded changes

86,510 on record

Recorded policy changes, newest first
Recorded	Payer	Policy	Change
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Solid Tumors of ChildhoodPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-SOLID-TUMORS-OF-CHILDHOOD	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support for Primitive Neuroectodermal Tumors (PNET) & EpendymomaPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-FOR-PRIMITIVE-NEUROECTODERMAL-TUMORS-PNET-EPENDYMOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Non Hodgkin's LymphomasPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-NON-HODGKIN-S-LYMPHOMAS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support- Myelodysplastic SyndromePayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-MYELODYSPLASTIC-SYNDROME	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Hodgkin's DiseasePayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-HODGKIN-S-DISEASE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support, Germ Cell TumorsPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-GERM-CELL-TUMORS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem Cell Support Followed by Nonmyeloablative Allogeneic Stem Cell Transplant for Multiple MyelomaPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-CELL-SUPPORT-FOLLOWED-BY-NONMYELOABLATIVE-ALLOGENEIC-STEM-CELL-TRANSPLANT-FOR-MULTIPLE-MYELOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Ewing's SarcomaPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-EWING-S-SARCOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Chronic Myelogenous LeukemiaPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-CHRONIC-MYELOGENOUS-LEUKEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Acute Myelogenous LeukemiaPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-ACUTE-MYELOGENOUS-LEUKEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Autologous Stem &/or Progenitor Cell Support-Acute Lymphocytic LeukemiaPayerPolicy · ARKBLUE-HDC-AUTOLOGOUS-STEM-OR-PROGENITOR-CELL-SUPPORT-ACUTE-LYMPHOCYTIC-LEUKEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Solid Tumors of ChildhoodPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-SOLID-TUMORS-OF-CHILDHOOD	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support for Primitive Neuroectodermal Tumors (PNET) & EpendymomaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-FOR-PRIMITIVE-NEUROECTODERMAL-TUMORS-PNET-EPENDYMOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Non-Hodgkin's LymphomaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-NON-HODGKIN-S-LYMPHOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Myelodysplastic DiseasePayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-MYELODYSPLASTIC-DISEASE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Hodgkin's DiseasePayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-HODGKIN-S-DISEASE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem Cell Support-Hemophagocytic lymphohistiocytosisPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-CELL-SUPPORT-HEMOPHAGOCYTIC-LYMPHOHISTIOCYTOSIS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Genetic Diseases & Acquired AnemiasPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-GENETIC-DISEASES-ACQUIRED-ANEMIAS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Ewing's SarcomaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-EWING-S-SARCOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Chronic Myelogenous LeukemiaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-CHRONIC-MYELOGENOUS-LEUKEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic or Autologous Hematopoietic Stem Cell Support-Malignant Astrocytomas & GliomasPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-OR-AUTOLOGOUS-HEMATOPOIETIC-STEM-CELL-SUPPORT-MALIGNANT-ASTROCYTOMAS-GLIOMAS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic or Autologous Hematopoietic Stem Cell Support for Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-OR-AUTOLOGOUS-HEMATOPOIETIC-STEM-CELL-SUPPORT-FOR-CHRONIC-LYMPHOCYTIC-LEUKEMIA-AND-SMALL-LYMPHOCYTIC-LYMPHOMA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Acute Myelogenous LeukemiaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-ACUTE-MYELOGENOUS-LEUKEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	HDC & Allogeneic Stem &/or Progenitor Cell Support-Acute Lymphocytic LeukemiaPayerPolicy · ARKBLUE-HDC-ALLOGENEIC-STEM-OR-PROGENITOR-CELL-SUPPORT-ACUTE-LYMPHOCYTIC-LEUKEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Guselkumab (e.g., Tremfya )PayerPolicy · ARKBLUE-GUSELKUMAB-E-G-TREMFYA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Ground AmbulancePayerPolicy · ARKBLUE-GROUND-AMBULANCE	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Goserelin (e.g., Zoladex)PayerPolicy · ARKBLUE-GOSERELIN-E-G-ZOLADEX	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Golimumab (e.g., Simponi Aria)PayerPolicy · ARKBLUE-GOLIMUMAB-E-G-SIMPONI-ARIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Glofitamab-gxbm (e.g., Columvi)PayerPolicy · ARKBLUE-GLOFITAMAB-GXBM-E-G-COLUMVI	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Givosiran (e.g., GIVLAARI)PayerPolicy · ARKBLUE-GIVOSIRAN-E-G-GIVLAARI	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Testing for Heterozygous Familial HypercholesterolemiaPayerPolicy · ARKBLUE-GENETIC-TESTING-FOR-HETEROZYGOUS-FAMILIAL-HYPERCHOLESTEROLEMIA	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Whole Exome and Whole Genome SequencingPayerPolicy · ARKBLUE-GENETIC-TEST-WHOLE-EXOME-AND-WHOLE-GENOME-SEQUENCING	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Uveal Melanoma, Gene Expression Profile To Predict Risk Of MetastasisPayerPolicy · ARKBLUE-GENETIC-TEST-UVEAL-MELANOMA-GENE-EXPRESSION-PROFILE-TO-PREDICT-RISK-OF-METASTASIS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Use of Common Genetic Variants (Single Nucleotide Polymorphisms) to Predict Risk of Nonfamilial Breast CancerPayerPolicy · ARKBLUE-GENETIC-TEST-USE-OF-COMMON-GENETIC-VARIANTS-SINGLE-NUCLEOTIDE-POLYMORPHISMS-TO-PREDICT-RISK-OF-NONFAMILIAL-BREAST-CANCER	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: UGT1A1 to Predict Toxicity to Irinotecan (Invader Assay)PayerPolicy · ARKBLUE-GENETIC-TEST-UGT1A1-TO-PREDICT-TOXICITY-TO-IRINOTECAN-INVADER-ASSAY	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Testing for Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene FusionsPayerPolicy · ARKBLUE-GENETIC-TEST-TESTING-FOR-NEUROTROPHIC-RECEPTOR-TYROSINE-KINASE-NTRK-GENE-FUSIONS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients with CancerPayerPolicy · ARKBLUE-GENETIC-TEST-LABORATORY-AND-GENETIC-TESTING-FOR-USE-OF-5-FLUOROURACIL-IN-PATIENTS-WITH-CANCER	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Tamoxifen Treatment (CYP2D6)PayerPolicy · ARKBLUE-GENETIC-TEST-TAMOXIFEN-TREATMENT-CYP2D6	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Statin-Induced Myopathy (SLCO1B1)PayerPolicy · ARKBLUE-GENETIC-TEST-STATIN-INDUCED-MYOPATHY-SLCO1B1	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Rett SyndromePayerPolicy · ARKBLUE-GENETIC-TEST-RETT-SYNDROME	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: PTEN Hamartoma Tumor SyndromePayerPolicy · ARKBLUE-GENETIC-TEST-PTEN-HAMARTOMA-TUMOR-SYNDROME	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Inherited Thrombophilia, Factor V Leiden, Prothrombin Gene Mutations (G20210A) and MTHFR MutationsPayerPolicy · ARKBLUE-GENETIC-TEST-INHERITED-THROMBOPHILIA-FACTOR-V-LEIDEN-PROTHROMBIN-GENE-MUTATIONS-G20210A-AND-MTHFR-MUTATIONS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Proteogenomic Testing for Patients with Cancer (GPS Cancer Test)PayerPolicy · ARKBLUE-GENETIC-TEST-PROTEOGENOMIC-TESTING-FOR-PATIENTS-WITH-CANCER-GPS-CANCER-TEST	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Prenatal Analysis of Fetal DNA in Maternal Blood to Detect Fetal AneuploidyPayerPolicy · ARKBLUE-GENETIC-TEST-PRENATAL-ANALYSIS-OF-FETAL-DNA-IN-MATERNAL-BLOOD-TO-DETECT-FETAL-ANEUPLOIDY	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Preconception or Prenatal Testing as a Carrier ScreenPayerPolicy · ARKBLUE-GENETIC-TEST-PRECONCEPTION-OR-PRENATAL-TESTING-AS-A-CARRIER-SCREEN	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Pharmacogenetic TestingPayerPolicy · ARKBLUE-GENETIC-TEST-PHARMACOGENETIC-TESTING	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Molecular Testing for the Management of Pancreatic Cysts and Solid Pancreaticobiliary Lesions (PathFinderTG)PayerPolicy · ARKBLUE-GENETIC-TEST-MOLECULAR-TESTING-FOR-THE-MANAGEMENT-OF-PANCREATIC-CYSTS-AND-SOLID-PANCREATICOBILIARY-LESIONS-PATHFINDERTG	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: NeurofibromatosisPayerPolicy · ARKBLUE-GENETIC-TEST-NEUROFIBROMATOSIS	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Multiple Myeloma, Gene Expression ProfilingPayerPolicy · ARKBLUE-GENETIC-TEST-MULTIPLE-MYELOMA-GENE-EXPRESSION-PROFILING	New policy
Aug 2, 2026	Arkansas Blue Cross and Blue Shield	Genetic Test: Molecular Testing of Tumors for Genomic Profiling as a Therapeutic GuidePayerPolicy · ARKBLUE-GENETIC-TEST-MOLECULAR-TESTING-OF-TUMORS-FOR-GENOMIC-PROFILING-AS-A-THERAPEUTIC-GUIDE	New policy